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Clinical PerspectiveWhat Is New?Borderline and low normal ankle‐brachial index values are associated with reduced thigh muscle energy production in people free of overt cardiovascular diseaseThis supports evidence that mildly reduced ankle‐brachial index values are associated with adverse mitochondrial characteristics.What Are the Clinical Implications?Future study is needed to determine whether interventions that improve lower extremity perfusion or increase mitochondrial activity can prevent functional decline in persons with an ankle‐brachial index of 0.90 to 1.40.

Introduction {#jah32463-sec-0008}
============

In peripheral arterial disease (PAD), clinically defined as an ankle‐brachial index (ABI) \<0.90, chronically reduced blood flow to the lower extremities is associated with reduction in walking endurance.[1](#jah32463-bib-0001){ref-type="ref"} Limited walking endurance is associated with lower mitochondrial energy production,[2](#jah32463-bib-0002){ref-type="ref"}, [3](#jah32463-bib-0003){ref-type="ref"}, [4](#jah32463-bib-0004){ref-type="ref"} which is attributed to impaired oxygen delivery[5](#jah32463-bib-0005){ref-type="ref"} as well as intrinsic mitochondrial myopathy resulting from the repeated cycles of ischemia/reperfusion injury.[6](#jah32463-bib-0006){ref-type="ref"}

Growing literature also suggests that compared with those with a normal ABI (1.1--1.4), individuals with borderline ABI (0.90--0.99) and low normal ABI (1.00--1.09) are also more likely to have poor walking endurance, possibly attributable to subclinical atherosclerosis.[7](#jah32463-bib-0007){ref-type="ref"}, [8](#jah32463-bib-0008){ref-type="ref"}, [9](#jah32463-bib-0009){ref-type="ref"} Whether poorer walking performance previously observed in this group is also associated with impaired leg muscle mitochondrial function is unknown.

We hypothesize that as is the case in PAD with ABI \<0.90, an ABI of 0.90 to 1.10 is also associated with lower leg muscle mitochondrial energy production compared with an ABI of 1.11 to 1.40. To test this hypothesis, we examined the association between ABI and mitochondrial energy productions, assessed by phosphorus magnetic resonance spectroscopy (31P‐MRS), in participants of the BLSA (Baltimore Longitudinal Study of Aging), free of clinically overt PAD.

Methods {#jah32463-sec-0009}
=======

Sample {#jah32463-sec-0010}
------

We analyzed data from 363 men and women participating in the BLSA with ABIs between 0.90 and 1.40, who underwent post‐exercise phosphocreatine recovery rate (*k*PCr) measurement via 31P‐MRS of the thigh muscle and ABI testing. Participants were divided in 2 groups: those with an ABI of 0.90 to 1.09 and those with an ABI of 1.10 to 1.40. The overall design, study population, and measurement protocols of the BLSA have been previously reported.[10](#jah32463-bib-0010){ref-type="ref"} Briefly, the BLSA, established in 1958, is a continuous enrollment cohort study of community‐dwelling adults conducted by the National Institute on Aging Intramural Research Program. Participants with no major chronic conditions or functional impairments are enrolled in the study and follow‐up visits occur at intervals of 1 to 4 years, becoming more frequent for older participants. Trained and certified technicians administered all of the assessments, following standardized protocols. The institutional review board of the National Institute of Environmental Health Sciences approved the study protocol, and all participants gave written informed consent.

Ankle‐Brachial Index {#jah32463-sec-0011}
--------------------

Simultaneous bilateral brachial and ankle blood pressure (BP) measurements were performed as part of the routine diagnostic procedure to assess bilateral ABI using the oscillometric technique. After a 10‐minute resting period in the supine position, patients underwent 3 repeated BP measurements of both ankles and both arms taken simultaneously using a validated automatic oscillometric device (Colin VP‐2000; Colin Medical Technology). BP cuffs were applied to the arms and ankles of patients and BP was recorded in triplicates. The ABI was calculated as the average of the triplicate readings of resting ankle systolic pressure of the index leg divided by the average of the left and right arm resting brachial systolic pressure readings. We used left ABI for the primary analysis given that muscle spectroscopy was performed on the left thigh muscles; an alternative analysis was performed using the right ABI to examine for the specificity of the association with the ipsilateral readings.

31P‐Magnetic Resonance Spectroscopy {#jah32463-sec-0012}
-----------------------------------

Skeletal muscle mitochondrial energy production was measured using a previously described MRI method.[11](#jah32463-bib-0011){ref-type="ref"} In vivo spectra of phosphorous‐containing metabolites were acquired using a 3T Philips Achieva MR scanner (Philips) and a 10‐cm 31P‐tuned surface coil (PulseTeq) fastened over the left thigh vastus lateralis muscle. Participants performed a rapid ballistic knee extension exercise while lying supine in the bore of the magnet; this maneuver was practiced before entering the magnet.[11](#jah32463-bib-0011){ref-type="ref"}, [12](#jah32463-bib-0012){ref-type="ref"} A series of pulse‐acquire 31P spectra were obtained before, during, and after the knee extension exercise. The pulse sequence consisted of adiabatic radiofrequency excitation pulses with a 90‐degree flip angle, for 300 acquisitions, with a repetition time of 1.5 seconds; signal averaging over 4 successive acquisitions for signal‐to‐noise ratio enhancement, gave effectively 75 spectra obtained with a temporal resolution of 6 seconds. The length of exercise was monitored to achieve between a 33% to 66% reduction in phosphocreatine (PCr) peak height (and never exceeded 42 seconds), with a post‐exercise recovery period of 5.8 to 6.3 minutes. Spectra were processed using jMRUI (version 5.0), and metabolites were quantified using a nonlinear least‐squares algorithm (AMARES).[13](#jah32463-bib-0013){ref-type="ref"}, [14](#jah32463-bib-0014){ref-type="ref"}

### Skeletal muscle oxidative ATP resynthesis rate determined by 31P‐MRS {#jah32463-sec-0013}

The recovery rate for phosphocreatine was calculated by fitting the post‐exercise time‐dependent change in PCr to a mono‐exponential function of the form:$$\text{PCr}\,(t) = \text{PCr}0 + \Delta\text{PCr}\,(1 - \text{exp}\,( - t/\mathit{\tau}\text{PCr}))$$where PCr0 is the end‐of‐exercise PCr signal area (ie, the PCr signal area at the beginning of the recovery period), ΔPCr is the decrease in signal area from its pre‐exercise baseline value of PCrbaseline to PCr0 resulting from in‐magnet exercise, and τPCr is the PCr exponential recovery time constant. The inverse of τPCr, *k*PCr (=1/τPCr) is thus the recovery rate constant. Greater *k*PCr reflects shorter recovery time, and hence higher mitochondrial energy production. This is taken as an index of in vivo muscle oxidative phosphorylation capacity, as there are minimal other energy demands during this resting period. *k*PCr resynthesis is primarily considered a function of maximum mitochondrial ATP production with no or minimal contribution of anaerobic metabolism.[15](#jah32463-bib-0015){ref-type="ref"}, [16](#jah32463-bib-0016){ref-type="ref"}, [17](#jah32463-bib-0017){ref-type="ref"}, [18](#jah32463-bib-0018){ref-type="ref"}, [19](#jah32463-bib-0019){ref-type="ref"}, [20](#jah32463-bib-0020){ref-type="ref"} The percentage of PCr depletion was calculated as the decrease in the PCr peak area from pre‐exercise PCrbaseline to PCr0.[21](#jah32463-bib-0021){ref-type="ref"}, [22](#jah32463-bib-0022){ref-type="ref"} Intramuscular pH was also monitored (calculated according to the chemical shift of inorganic phosphate, Pi, relative to PCr) to ensure that intramuscular pH did not drop below 6.80.[23](#jah32463-bib-0023){ref-type="ref"}

Clinical Variables {#jah32463-sec-0014}
------------------

Height and weight were objectively measured per standard protocols. Body mass index was determined as kilograms per square meter. Patients were classified as current, former, or never smokers. The use of medications was determined at each study visit. Diabetes mellitus was defined as meeting 2011 American Diabetes Association criteria[24](#jah32463-bib-0024){ref-type="ref"} or the use of diabetes mellitus medications. Hypercholesterolemia was defined as a total serum cholesterol level of 200 mg/dL or the use of lipid‐lowering treatment.

Laboratory Studies {#jah32463-sec-0015}
------------------

Fasting plasma glucose, triglyceride, total cholesterol, and high‐density lipoprotein cholesterol levels were measured. Low‐density lipoprotein cholesterol concentrations were estimated using the Friedewald formula.[25](#jah32463-bib-0025){ref-type="ref"}

Statistical Analyses {#jah32463-sec-0016}
--------------------

Descriptive characteristics and *k*PCr values were compared between participants with an ABI of 0.90 to 1.10 and those with an ABI of 1.11 to 1.40 using Student *t* test and chi‐square statistics. Bivariate correlation between *k*PCr and left and right ABIs was performed to examine the specificity of the association between left thigh *k*PCr with ipsilateral versus contralateral ABI. To test whether the difference in *k*PCr between the 2 groups was independent of other covariates, we used general linear models with ABI as a categorical variable (ie, ABI 0.90--1.10 versus ABI 1.11--1.40) to compute and compare the least‐square means (marginal means) of *k*PCr for both categories adjusting for age, sex, race, smoking status, diabetes mellitus, hypertension, body mass index, and cholesterol levels. To examine whether the association between ABI and *k*PCr displays a threshold effect or whether it persists in an ABI range of 1.11 to 1.40, we fit linear regression models, using *k*PCr and ABI as continuous variables, in the larger ABI range of 0.90 to 1.40 and limited to the group with an ABI of 1.11 to 1.40. ABI was entered as a quadratic term to test for nonlinearity in the association and removed from the model when nonsignificant. All analyses were performed with SAS for Windows (version 9.3; SAS Institute Inc).

Results {#jah32463-sec-0017}
=======

Descriptive characteristics are shown on Table [1](#jah32463-tbl-0001){ref-type="table-wrap"}. The sample included 363 participants with a mean age of 71±12 years; 18% of the participants had diabetes mellitus and 3.2% were current and 36.9% were former smokers. A total of 37% depletion of PCr was observed with exercise with a recovery rate constant (*k*PCr) of 20.6 ms^−1^. These findings are consistent with reports from similar populations.[16](#jah32463-bib-0016){ref-type="ref"}, [26](#jah32463-bib-0026){ref-type="ref"} The average ABI was 1.16±0.08, with 82 participants (22%) having ABI of 0.90 to 1.10. Compared with participants with an ABI of 1.11 to 1.40, those with an ABI of 0.90 to 1.11 included a higher prevalence of women (73% versus 54.1%, *P*=0.001) and had slower PCr recovery (19.3 versus 20.8 ms^−1^, *P*=0.015), with no difference in percentage of PCr depletion. Interestingly, while left and right ABI were strongly correlated (*r*=0.75, *P*\<0.001), *k*PCr was significantly correlated with the ipsilateral, left ABI (*r*=0.12, *P*=0.003); however, the association was weaker and marginally significant with the contralateral ABI (*r*=0.075, *P*=0.073) (Table [2](#jah32463-tbl-0002){ref-type="table-wrap"}). The rest of the analysis was performed using left ABI, referred to simply as ABI. Figure [1](#jah32463-fig-0001){ref-type="fig"} shows that the difference in *k*PCr between the 2 groups remained significant using least‐square means adjusted for age, sex, race, diabetes mellitus, smoking status, body mass index, mean brachial BP, and cholesterol levels. There was no significant interaction between sex and ABI in the association with *k*PCr (data not shown).

###### 

Descriptive Characteristics

  Variable                   Total (N=363)   ABI 0.9 to 1.01 (n=82)   ABI 1.1 to 1.4 (n=281)   *P* Value
  -------------------------- --------------- ------------------------ ------------------------ -----------
  Age                        71.0±12.7       71.9±14.8                71.3±12.1                0.7027
  Women                      212 (58.4)      60 (73.2)                152 (54.1)               0.0012
  White race                 247 (68.0)      56 (68.3)                191 (67.9)               0.6864
  Smoking                                                                                      0.7967
  Never                      206 (59.9)      48 (61.5)                161 (59.1)               
  Former                     127 (36.9)      28 (35.9)                101 (37.6)               
  Current                    11 (3.2)        2 (2.6)                  10 (3.3)                 
  Left ABI                   1.16±0.08       1.05±0.04                1.19±0.06                \<0.0001
  *k*PCr, ms^−1^             20.6±0.005      19.3±5.6                 20.8±4.7                 0.0146
  PCr depletion, %           37.7±11.1       37.5±11.0                37.5±11.1                0.9640
  Brachial SBP               119.3±14.4      120.3±16.2               119.5±14.3               0.6809
  Hypertension               135 (38.9)      30 (39.5)                105 (38.8)               0.7059
  Hypertension treatment     122 (90.0)      28 (93.0)                94 (89.5)                0.4564
  Diabetes mellitus          64 (18.4)       11 (14.5)                53 (19.6)                0.6117
  Glucose, mg/dL             90.44±16.4      91.4±25.2                90.1±12.8                0.5055
  LDL cholesterol, mg/dL     98.7±31.7       103.6±32.9               97.0±31.4                0.1006
  HDL cholesterol, mg/dL     62.7±17.8       63.1±18.1                62.6±17.6                0.8578
  Total cholesterol, mg/dL   180.2±36.8      185.6±37.1               178.4±36.6               0.1235
  BMI, kg/m^2^               29.7±4.1        26.4±4.2                 26.8±4.1                 0.4083

ABI indicates ankle‐brachial index; BMI, body mass index; HDL, high‐density lipoprotein; *k*PCr, post‐exercise phosphocreatine recovery rate constant of the thigh muscle; LDL, low‐density lipoprotein; PCr, phosphocreatine recovery rate constant; SBP, systolic blood pressure.

###### 

Correlation Matrix

              Age   *k*PCr                                            Left ABI                                         Right ABI
  ----------- ----- ------------------------------------------------- ------------------------------------------------ ------------------------------------------------
  Age         1     −0.30731[a](#jah32463-note-0003){ref-type="fn"}   0.05338                                          0.0092
  *k*PCr            1                                                 0.12282[b](#jah32463-note-0004){ref-type="fn"}   0.07587
  Left ABI                                                            1                                                0.75336[a](#jah32463-note-0003){ref-type="fn"}
  Right ABI                                                                                                            1

ABI indicates ankle‐brachial index; *k*PCr, post‐exercise phosphocreatine recovery rate constant of the thigh muscle.

*P*\<0.0001.

*P*\<0.001.

![Least‐square means and standard errors of post‐exercise phosphocreatine recovery rate constant (*k*PCr) in patients with an ankle‐brachial index (ABI) 0.9 to 1.1 (black bar) and patients with an ABI\>1.1 (white bar), adjusting for age, sex, race, diabetes mellitus, smoking, and body mass index.](JAH3-6-e006604-g001){#jah32463-fig-0001}

To examine whether the association between ABI and *k*PCr has a threshold effect, we performed bivariate and multivariate linear regression analysis predicting *k*PCr among participants with an ABI of 0.90 to 1.40 and among those with an ABI of 1.10 to 1.40. ABI was linearly associated with *k*PCr in a bivariate analysis (Figure [2](#jah32463-fig-0002){ref-type="fig"}). Similarly, multivariate analysis showed that ABI was significantly associated with *k*PCr (standardized coefficient \[B\]=0.15, *P*=0.0027) adjusting for the covariates mentioned above (Table [3](#jah32463-tbl-0003){ref-type="table-wrap"}). The association was linear across the ABI range of 0.90 to 1.40, evidenced by the nonsignificant quadratic term for ABI in the model (data not shown). The association between ABI and *k*PCr remained significant when the analysis was restricted to the ABI range of 1.11 to 1.40 (Table [3](#jah32463-tbl-0003){ref-type="table-wrap"}).

![Linear regression analysis showing the association between post‐exercise phosphocreatine recovery rate constant (*k*PCr) of the thigh muscle with ankle‐brachial index.](JAH3-6-e006604-g002){#jah32463-fig-0002}

###### 

Linear Regression Model Predicting *k*PCr

                           ABI 0.9 to 1.4 (N=363)   ABI 1.1 to 1.4 (N=281)                              
  ------------------------ ------------------------ ------------------------ ---------- ------- ------- ----------
  Age                      −0.13                    −0.28                    \<0.0001   −0.14   −0.37   \<0.0001
  Men                      0.46                     0.04                     0.3484     0.93    0.09    0.1334
  White race               1.91                     0.16                     0.0011     1.19    0.12    0.0492
  PCr depletion, %         −0.13                    −0.29                    \<0.0001   −0.12   −0.29   \<0.0001
  ABI                      8.4                      0.15                     0.0027     9.0     0.12    0.0405
  Smoking, ever            −0.11                    −0.01                    0.8146     0.14    0.018   0.7565
  Diabetes mellitus        0.01                     0.001                    0.9982     0.36    0.03    0.6069
  BMI, kg/m^2^             −0.03                    −0.03                    0.5622     −0.04   −0.04   0.5711
  HR, beats per min        −0.06                    −0.11                    0.0202     −0.06   −0.10   0.0705
  MAP, mm Hg               0.03                     0.08                     0.085      0.04    0.08    0.1453
  LDL cholesterol, mg/dL   0.01                     0.05                     0.2847     0.01    0.08    0.1563
  HDL cholesterol, mg/dL   0.01                     0.04                     0.4700     0.01    0.04    0.5549
  Triglycerides, mg/dL     0.006                    0.05                     0.3141     0.006   0.06    0.3194

ABI indicates ankle brachial index; BMI, body mass index; HDL, high‐density lipoprotein; HR, heart rate; *k*PCr, post‐exercise phosphocreatine recovery rate constant of the thigh muscle; LDL, low‐density lipoprotein; MAP, mean arterial pressure; PCr, phosphocreatine recovery rate constant.

Β, nonstandardized coefficients.

B, standardized β coefficients.

Discussion {#jah32463-sec-0018}
==========

Main Findings {#jah32463-sec-0019}
-------------

This analysis shows a statically significantly lower muscle mitochondrial energy production in persons with a modestly reduced ABI of 0.90 to 1.09 compared with those with an ABI of 1.10 to 1.40. These findings suggest the possibility that a modestly lower ABI in the absence of overt PAD may have a negative association with mitochondria function. Interestingly, in this study, the positive association between ABI and lower muscle energy production was linear along the entire ABI range of 1.10 to 1.40.

Lower ABI is Linearly Associated With Reduced Mitochondrial Energy Production {#jah32463-sec-0020}
-----------------------------------------------------------------------------

These findings expand on previous reports showing a significant reduction in mitochondrial energy production in patients with PAD[2](#jah32463-bib-0002){ref-type="ref"}, [3](#jah32463-bib-0003){ref-type="ref"}, [4](#jah32463-bib-0004){ref-type="ref"} and suggest that even modest alterations in lower extremity perfusion may cause reduced muscle mitochondrial energy production.

The mechanism that links ABI with muscle mitochondrial energetics is not clear. There is a debate on whether the reduced mitochondrial energy production in PAD is a result of decreased perfusion and oxygen delivery during exercise or results from intrinsic mitochondrial impairment caused by repetitive cycles of ischemia‐reperfusion injury.[2](#jah32463-bib-0002){ref-type="ref"} Decreased perfusion via cuff‐induced stenosis causes a reduction in post‐exercise mitochondrial energy production in healthy men and women, supporting the notion that reduced oxygen delivery during exercise affects mitochondrial function.[5](#jah32463-bib-0005){ref-type="ref"} Further studies with assessment of leg arterial anatomy and flow are needed to examine whether a modest reduction in ABI is a result of subclinical flow limiting lesion in arteries of the lower extremities.

An additional explanation of the linear association between ABI and mitochondrial function within the "normal" range is that a modest reduction in ABI is a marker of arterial stiffness, which has been associated with universal organ dysfunction with aging, and not restricted to the legs. A normal ABI (1.10--1.40) reflects physiologic pulse pressure amplification, ie, higher systolic BP, in distal versus proximal arterial sites.[8](#jah32463-bib-0008){ref-type="ref"}, [27](#jah32463-bib-0027){ref-type="ref"} This phenomena is caused by the stiffer peripheral versus central arteries and by wave reflection hemodynamics that amplify pressure to a greater extent in distal versus proximal arterial sites. Given the profound central arterial stiffening and alterations to wave reflection dynamics with aging,[28](#jah32463-bib-0028){ref-type="ref"} peripheral amplification and subsequently ABI are reduced. Hence, a modest reduction in ABI within the range of 1.1 to 1.4 could also be a marker of central arterial stiffness, and not necessarily a reflection of limb‐specific flow impairment. Further studies with a larger sample size and repeated measures are needed to examine whether measures of arterial stiffness and pulse pressure amplification explain the association between ABI and mitochondrial energy production and functional capacity.

Reduced Mitochondrial Energy Production as a Potential Link Between Low ABI and Impaired Walk Endurance {#jah32463-sec-0021}
-------------------------------------------------------------------------------------------------------

McDermott et al[29](#jah32463-bib-0029){ref-type="ref"} have shown that an ABI between 0.90 and 1.10 was associated with reduced functional capacity measured by 6‐meter walking speed. Furthermore, an ABI of 0.90 to 1.10 was prospectively associated with a greater decline in 6‐minute walk performance as well as a greater risk for developing mobility loss over 5 years, when compared with an ABI of 1.11 to 1.40.[9](#jah32463-bib-0009){ref-type="ref"} These findings suggest that a gradual decline in ABI may be a marker of subclinical atherosclerotic disease in the lower extremities as well as in other organs that cumulatively affect lower extremity performance.[8](#jah32463-bib-0008){ref-type="ref"}

Our findings suggest that a possible modest restriction of blood flow with lower ABI could potentially compromise muscle mitochondrial function and directly contribute to poorer walking function in this group. We have previously reported, using data from the same cohort, that reduced mitochondrial energy production was associated with less exercise endurance, assessed by 400‐meter walking speed.[30](#jah32463-bib-0030){ref-type="ref"} Future studies are needed to demonstrate whether modest reduction of ABI when associated with impaired mitochondrial function predicts the risk of developing overt PAD. In addition, our findings raise the question of whether persons with ABIs of 0.90 to 1.10 would benefit from interventions aimed at preventing further mitochondrial damage and, therefore, its functional consequences and perhaps even full development of PAD.

Strengths and Limitations {#jah32463-sec-0022}
-------------------------

To our knowledge, this is the first study to examine the relationship between skeletal muscle mitochondrial energy production assessed by 31P‐MRS of thigh muscle and ABI over the range of ABI of 0.90 to 1.40. However, it is important to consider the study limitations. This is a cross‐sectional analysis; hence, inferences regarding causality cannot be made. The design of the BLSA prevented the inclusion of participants with PAD, which would have provided a wider range of ABI and *k*PCr. However, we believe that this topic has been studied in a PAD population, making the findings of this report complementary to those previously reported.

In addition, the magnitude of difference between the 2 groups is smaller compared with that reported between normal and PAD. While this is expected, it raises questions about the clinical relevance of these findings. We have previously reported, using data from this cohort, that *k*PCR was strongly associated with 400‐meter walking speed,[30](#jah32463-bib-0030){ref-type="ref"} which suggests that even such variations in this normal range might underlie subclinical alterations in function. We are in the process of collecting longitudinal data of ABI, mitochondrial function, and walking endurance from a larger sample, which will allow further elaboration on these findings.

Another limitation of our study is that mitochondrial testing was performed on the thigh muscle. This is likely to be affected only by proximal flow limitation compared with calf muscles, which are more frequently involved. Last, we measured ABI using the oscillometric rather than the auscultatory technique. This technique does not provide separate tibial and peroneal measures. However, the oscillometric technique has the clear advantage of being less operator dependent.

Perspectives {#jah32463-sec-0023}
------------

An ABI of 0.91 to 1.10 is associated with reduced mitochondrial energy production. The association between lower ABI and reduced mitochondrial energy production is also evident in the normal ABI range of 1.11 to 1.40. Further studies are needed to examine whether this subclinical decline in mitochondrial energy production is associated with future decline in walking endurance and the development of PAD symptomatology.
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